AstraZeneca heralds Tagrisso's OS lead over old TKIs in lung cancer niche
BARCELONA — AstraZeneca is drawing the curtains on just how much longer Tagrisso can help non-small cell lung cancer patients live compared to first-generation tyrosine kinase inhibitors targeting the EGFR mutation, making a strong case for its frontline use in this niche.
Having previously scored on the primary endpoint of PFS, the pharma giant is spelling out the OS data at ESMO Congress 2019: 38.6 months with Tagrisso versus 31.8 months on Tarceva or Iressa, giving rise to a hazard ratio of 0.799 (p=0.0462).
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,800+ biopharma pros reading Endpoints daily — and it's free.